A phase I/II study of 10-min dosing of bendamustine hydrochloride (rapid infusion formulation) in patients with previously untreated indolent B-cell non-Hodgkin lymphoma, mantle cell lymphoma, or relapsed/refractory diffuse large B-cell lymphoma in Japan

PURPOSE: This phase I/II clinical study was conducted to examine the safety, tolerability, pharmacokinetics, and efficacy of 10-min dosing of bendamustine in patients with previously untreated indolent B-cell non-Hodgkin lymphoma (iNHL) or mantle cell lymphoma (MCL) (Group 1) and patients with relap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishizawa, Kenichi, Yokoyama, Masahiro, Kato, Harumi, Yamamoto, Kazuhito, Makita, Masanori, Ando, Kiyoshi, Ueda, Yasunori, Tachikawa, Yoshimichi, Suehiro, Youko, Kurosawa, Mitsutoshi, Kameoka, Yoshihiro, Nagai, Hirokazu, Uoshima, Nobuhiko, Ishikawa, Takayuki, Hidaka, Michihiro, Ito, Yoshikiyo, Utsunomiya, Atae, Fukushima, Koji, Ogura, Michinori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300521/
https://www.ncbi.nlm.nih.gov/pubmed/35796785
http://dx.doi.org/10.1007/s00280-022-04442-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300521/
https://www.ncbi.nlm.nih.gov/pubmed/35796785
http://dx.doi.org/10.1007/s00280-022-04442-2

Ejemplares similares